Krämer, Julia
Bar-Or, Amit http://orcid.org/0000-0001-7179-0335
Turner, Timothy J. http://orcid.org/0000-0001-9770-2647
Wiendl, Heinz http://orcid.org/0000-0003-4310-3432
Article History
Accepted: 9 March 2023
First Online: 13 April 2023
Competing interests
: J.K. declares that she has received honoraria for lecturing from Biogen, Merck, Mylan, Novartis, Roche, Sanofi and Teva and has received financial research support from Amicus Therapeutics and Sanofi. A.B.-O. declares that he has received grant support to the University of Pennsylvania from Biogen Idec, EMD Serono, Novartis and Roche Genentech. He has participated as a speaker in meetings sponsored by and received consulting fees from Accure, Atara Biotherapeutics, Biogen, Bristol-Myers Squibb, GlaxoSmithKline, Gossamer, Janssen, Medimmune, EMD Serono, Novartis, Roche Genentech and Sanofi. T.J.T. is an employee of and may have ownership interests in Sanofi. H.W. declares that he has acted as a member of the Scientific Advisory Boards of Abbvie, Alexion, Argenx, Bristol Myers Squibb, Janssen, Merck and Novartis. He also declares that he has received speaker’s honoraria and travel support from Alexion, Biogen, Bristol-Myers Squibb, F. Hoffmann-La Roche, Genzyme, Merck, Neurodiem, Novartis, Roche, Teva and WebMD Global and acts as a paid consultant for Abbvie, Actelion, Argenx, Biogen, Bristol-Myers Squibb, EMD Serono, Fondazione Cariplo, Gossamer Bio, Idorsia, Immunic, Immunovant, Janssen, Lundbeck, Merck, NexGen, Novartis, PSI Contract Research Organization, Roche, Sanofi, UCB and Worldwide Clinical Trials. His research is funded by Alexion, Amicus Therapeutics, Argenx, Biogen, CSL Behring, F. Hoffmann-La Roche, Genzyme, Merck, Novartis, Roche and UCB.
Free to read: This content has been made available to all.